Circulatory system

CymaBay Announces Appointment of Charles McWherter, Ph.D. to Chief Scientific Officer and President of Research and Development

Retrieved on: 
Tuesday, November 1, 2022
Security (finance), SUGEN, Annual report, Development, Primary biliary cholangitis, Knowledge, PBC, Food and Drug Administration, U.S. Securities and Exchange Commission, Liver, GLOBE, Hepatitis, Liver disease, Fibrosis, Circulatory system, Research and development, Drug discovery, Priority, NASDAQ, Therapy, European Medicines Agency, Pfizer, Cornell University, Patient, Senior, CSO, Conditional sentence, Pharmaceutical industry, Medical device, Research

We are excited to announce the promotion of Chuck to President of Research and Development, in addition to his continuing role as Chief Scientific Officer.

Key Points: 
  • We are excited to announce the promotion of Chuck to President of Research and Development, in addition to his continuing role as Chief Scientific Officer.
  • Chuck joined CymaBay in 2007 and has served as Chief Scientific Officer since 2013.
  • It is a privilege to be given the opportunity to lead the talented and experienced R&D team at CymaBay.
  • From 2007 to 2013, he served as Senior Vice President, Research and Preclinical Development.

China Pharmaceutical Contract Manufacturing Market Report 2022: Increasing Prevalence of Non-Communicable Diseases Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 1, 2022
Health, Pharmaceutical, MSD, API, Quality control, Growth, World Health Organization, Heart, Vericiguat, Merck, Cancer, CVD, Bayer, Degenerative disease, SGC, WHO, Circulatory system, LDL, World, MAH, Government, Prostate cancer, Incidence, CAGR, Merck & Co., Vaccine, Patient, Triglyceride, Prevalence, OTC, Drug development, Drug discovery, Cardiovascular disease, Fine chemical, Pharmaceutical industry

The China pharmaceutical contract manufacturing market is growing at a CAGR of around 12.1% during the forecast period.

Key Points: 
  • The China pharmaceutical contract manufacturing market is growing at a CAGR of around 12.1% during the forecast period.
  • The major factor that drives the growth of the market includes the major companies in the pharmaceutical contract manufacturing market are expanding their manufacturing capacity in China.
  • It shows the efforts of China contract manufacturers towards drug development, which in turn is projected to increase the China pharmaceutical contract manufacturing market.
  • Among product types, the API segment is estimated to be the dominating segment in the China pharmaceutical contract manufacturing market.

Microbot Medical Adds the Head of the Interventional Radiology Unit of Europe’s Largest Cancer Center, Dr. Thierry Jacques De Baère to its Scientific Advisory Board

Retrieved on: 
Monday, October 31, 2022
CVIR, U.S. Securities and Exchange Commission, SAB, ESMO, Intellectual property, Cardiovascular and Interventional Radiological Society of Europe, Physician, Robotics, Radiation exposure, MD, Adoption, Research, Journal, Private Securities Litigation Reform Act, Failure, CEO, Circulatory system, Forward-looking statement, Maintenance, Interventional radiology, Patient, SEC, Federal, Cancer, European Society of Radiology, Vision Guided Robotic Systems, Goal, 1, Company, Security (finance), CIRSE, Coronavirus Scientific Advisory Board (Turkey), GLOBE, Oncology, Doctor of Philosophy, Growth, NASDAQ, FDA, Technology, Time-invariant system, COVID-19, KOL, Nasdaq, European Society for Medical Oncology, Medicine, Medical device, Microbotics

HINGHAM, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), which is continuing to expand its Key Opinion Leader (KOL) support network, today announced that Thierry Jacques De Baère, MD, PhD, is joining the Company’s Scientific Advisory Board (SAB). Dr. De Baère is head of the Interventional Radiology Unit at Institut Gustave Roussy Cancer Center in Villejuif, France, the largest cancer center in Europe. The Company’s SAB now includes 11 members from the U.S., Europe and Israel, who support the rising momentum for the Company’s LIBERTY® Robotic System.

Key Points: 
  • Dr. De Bare is head of the Interventional Radiology Unit at Institut Gustave Roussy Cancer Center in Villejuif, France, the largest cancer center in Europe.
  • The Companys SAB now includes 11 members from the U.S., Europe and Israel, who support the rising momentum for the Companys LIBERTY Robotic System.
  • Dr. De Bare is a leader in the endovascular space, who realized the potential of the LIBERTY Robotic System after his own personal experience.
  • Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.

U.S. Patent for Bioelectric Expression of Klotho, a Key Longevity and Disease-Fighting Protein Issued to Leonhardt Ventures

Retrieved on: 
Thursday, October 20, 2022
Sleep apnea, Muscle tissue, Breast augmentation, Depression, Brain, Program, CEO, Patent, Wellness, Personal care, Neurogenic bladder dysfunction, CA, LLC, Invention, Cancer, Mouse, Marketing, Mentorship, United States Patent and Trademark Office, Sleep-related breathing disorder, Skin, GLOBE, Liver failure, FDA, Leonhardt, Time, Amnesia, Stroke, Kidney failure, Cabinet Secretary for Covid Recovery, Research, Regeneration, Procell, Technology, Addiction, Neurology, Body Electric, USPTO, Ageing, Muscle atrophy, Launch pad, Circulatory system, Education, OEM, Lists of diseases, Patient, Biotechnology, Erectile dysfunction, 1836 U.S. Patent Office fire, Partnership, Diabetes, Safety, Heart, Pharmaceutical industry, Dietary supplement, Medical device, Klotho, Longevity

11,471,686 covering bioelectric stimulation control of increasing Klotho, a protein must known for muscle regeneration and other powerful anti-aging properties.

Key Points: 
  • 11,471,686 covering bioelectric stimulation control of increasing Klotho, a protein must known for muscle regeneration and other powerful anti-aging properties.
  • "This Klotho patent adds significant support to our goal mission to help people live longer and healthier lives.
  • In landmark studies, mice deficient in Klotho exhibited accelerated aging and died 30% sooner than mice with normal Klotho levels.
  • The company also intends to launch a chain of Longevity and Wellness MedSpas based on its proprietary core technologies in 2024.

Portfolio Highlights: Clinical and Financial Updates of ABM, F5, AceLink, HAYA, Regenacy, and Arthrosi

Retrieved on: 
Wednesday, September 28, 2022
DPN, Safety, Ageing, Kidney, HDAC, Industry, Patient, Sickle cell disease, Technology, Uric acid, Metastasis, Peripheral neuropathy, Classification, Brain, Disease, Movement disorders, Lists of diseases, Inflammation, Fibrosis, Food, Leukemia, RNA, Traffic barrier, Circulatory system, HDAC6, Diabetes, Neurodegeneration, ODD, Risk, FDA, BRAF, Cancer, Drug discovery, Genome, Gout, ACR, Therapy, Fabry, Fabry disease, Facet joint arthrosis, Cros, ABM, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CLSA, Protein, CA, Pharmacokinetics, Listeria monocytogenes non-coding RNA, Pharmaceutical industry, Vaccine, F5

ABM-1310, ABM Therapeutic's proprietary clinical candidate developed as a next-generation BRAF inhibitor, is a highly selective, highly water-soluble, orally administrated, and brain-penetrant small molecule BRAF inhibitor.

Key Points: 
  • ABM-1310, ABM Therapeutic's proprietary clinical candidate developed as a next-generation BRAF inhibitor, is a highly selective, highly water-soluble, orally administrated, and brain-penetrant small molecule BRAF inhibitor.
  • F5 Therapeutics, which invested and incubated by Viva BioInnovator, was recently awarded the first Servier FAST Discovery Award.
  • Winning this award means F5 stood out from 23 applications, indicating the industry's recognition of F5's innovative treatment methods in the field of biomedicine.
  • AceLink Therapeutics, Inc. (AceLink), invested and incubated by Viva BioInnovator, is an innovative biopharmaceutical company developing transformative therapies for genetic diseases.

Cytokinetics Announces Upcoming Presentations at the 2022 Inaugural HCM Society Scientific Sessions and the HFSA Annual Scientific Meeting

Retrieved on: 
Monday, September 26, 2022
YouTube, Safety, Act, Heart Failure Society of America, Doctor of Philosophy, The Act, National Harbor, Maryland, Twitter, Mechanics, FDA, Sale, Safe harbor, Cytokinetics, Muscle weakness, Cohort, LinkedIn, Intellectual property, Private Securities Litigation Reform Act, NDA, Heart failure, U.S. Securities and Exchange Commission, Circulatory system, Facebook, History, Clinical study design, Hypertrophic cardiomyopathy, Pharmacology, SAN, ALS, Research, HCM, GLOBE, Security (finance), University, School, Patent, OLE, Multisystemic smooth muscle dysfunction syndrome, Pharmaceutical industry, Obstruction, MD, Patient

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced six upcoming presentations, including two presentations at the 2022 Inaugural HCM Society Scientific Sessions, held by this newly launched professional medical society in National Harbor, MD on September 30, 2022, and four presentations at the Heart Failure Society of America (HFSA) Annual Scientific Meeting taking place in Washington, D.C. from September 30, 2022 to October 3, 2022.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced six upcoming presentations, including two presentations at the 2022 Inaugural HCM Society Scientific Sessions, held by this newly launched professional medical society in National Harbor, MD on September 30, 2022, and four presentations at the Heart Failure Society of America (HFSA) Annual Scientific Meeting taking place in Washington, D.C. from September 30, 2022 to October 3, 2022.
  • Cytokinetics is also developing aficamten, a next-generation cardiac myosin inhibitor, for the potential treatment of hypertrophic cardiomyopathies (HCM).
  • Cytokinetics expects to start a Phase 3 clinical trial of aficamten in patients with obstructive HCM in Q4 2021.
  • CYTOKINETICS and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Global White Biotechnology Market Report 2022: Increasing demand for Biofuels and Green Chemicals Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 22, 2022
Health, Biotechnology, Observation, Global, Porter's five forces analysis, COVID-19, Urology, Risk, Geography, Growth, Ansoff Matrix, Industry, Market development, Industrial enzymes, USD, Investment, SWOT, Circulatory system, CAGR, Fine chemical, Retail, Risk management, Neurovascular bundle, Application, Biofuel

The Global White Biotechnology Market is segmented based on Product, Application, and Geography.

Key Points: 
  • The Global White Biotechnology Market is segmented based on Product, Application, and Geography.
  • The report presents a detailed Ansoff matrix analysis for the Global White Biotechnology Market.
  • The Global White Biotechnology Market is analyzed using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • The report offers a comprehensive evaluation of the Global White Biotechnology Market.

Aristea Therapeutics Strengthens its Board of Directors with the Appointment of Three Accomplished Biopharma Leaders From Poseida Therapeutics, Novo Holdings and Pfizer

Retrieved on: 
Wednesday, August 24, 2022
CEO, BMS, Venture capital, University of Minnesota Law School, Pfizer, Amylin Pharmaceuticals, Science, Genetic engineering, Partner, Leadership, PPP, Patient, Circulatory system, Conditional sentence, Brigham and Women's Hospital, Bristol Myers Squibb, Degenerative disease, HS, Board, MIT, Immunology, Roche, Hospital, Medicine, Heis, Hidradenitis suppurativa, University, Partnership, CA, LP, Therapy, Tufts University School of Medicine, Inflammation, Investment, MD, Amgen, Acquisition, Drug development, Lists of diseases, Novo Holdings A/S, Center, Minot State University, CNS, Arena Pharmaceuticals, Pharmaceutical industry, Aristea, Gastroenterology, Director, Indiana University, Rheumatology, Neuroscience

Mr. Gergen will take an independent board seat, and Dr. O'Connell will take a seat on behalf of Novo Holdings.

Key Points: 
  • Mr. Gergen will take an independent board seat, and Dr. O'Connell will take a seat on behalf of Novo Holdings.
  • Heis currently the CEO of Poseida Therapeutics, a genetic engineering company developing novel cell and gene therapies with the capacity to cure.
  • Aristea Therapeutics (Air-iss-tay-uh) is a clinical-stage immunology focused drug development company developing novel therapies to treat serious inflammatory diseases.
  • In March 2022, Arena Pharmaceuticals was acquired by Pfizer Inc. As such, the partnership and the option to acquire Aristea now sit with Pfizer.

Real World Evidence Solution Market Report 2022-2027: Rising Focus on End-To-End RWE Services & Emerging Roles of Wearable Devices and AI in RWE Presents Lucrative Growth Opportunities

Retrieved on: 
Tuesday, August 23, 2022
Circulatory system, Decision-making, Customer support, Determining the number of clusters in a data set, Data set, USD, Real, Research report, Business Growth Fund, Component, Value, Use, Neurology, CAGR, Market share analysis, Diagnosis, Strategic management, Acquisition, Growth, Retail, Oncology

This research report categorizes the Real World Evidence Solution to forecast the revenues and analyze the trends in each of the following sub-markets:

Key Points: 
  • This research report categorizes the Real World Evidence Solution to forecast the revenues and analyze the trends in each of the following sub-markets:
    Based on Component, the market was studied across Data Set and Services.
  • The Data Set is further studied across Claims Data, Clinical Settings Data, Patient-Powered Data, and Pharmacy Data.
  • Based on Therapeutic Area, the market was studied across Cardiovascular, Immunology, Infectious Diseases, Neurology, and Oncology.
  • Based on End-User, the market was studied across Biopharmaceutical Company, Clinical & Life Sciences Organization, and Diagnostics or Medical Device Company.

Global Cardiovascular Partnering 2015-2022: Deal Trends, Players and Financials - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 23, 2022
Health, Cardiology, Players, Technology, Cardiovascular disease, Finance, Collection, Biotechnology, Video game, Pharmaceutical industry, Circulatory system

The "Global Cardiovascular Partnering 2015-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cardiovascular Partnering 2015-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.
  • Global Cardiovascular Partnering 2015 to 2022 provides the full collection of Cardiovascular disease deals signed between the world's pharmaceutical and biotechnology companies since 2015.
  • The report takes readers through the comprehensive Cardiovascular disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Cardiovascular deals.
  • Global Cardiovascular Partnering 2015-2022: Deal trends, players and financials is intended to provide the reader with an in-depth understanding and access to cardiovascular trends and structure of deals entered into by leading companies worldwide.